


IN THE CLAIMS

The status of the claims is listed below.

Claim 1 (Currently Amended): A compound of the formula (I):



wherein R^1 is hydrogen or lower alkyl;

R² is lower alkyl optionally substituted with halogen, hydroxy, lower alkoxyimino or lower alkoxy; lower alkenyl; cycloalkyl; cyano; lower alkanoyl; cycloalkylcarbonyl; N,N-di(lower)alkylcarbamoyl; carbamoyl; N-lower alkoxy-N-lower alkylcarbamoyl; amino; di(lower)alkylamino; lower alkoxycarbonylamino; N,N-di(lower)alkylcarbamoylamino; N-(N,N-di(lower)alkylcarbamoyl)-N-lower alkylamino; halogen; hydroxy; carboxy; lower alkoxycarbonyl; aroyl; ~~heterocycliccarbonyl; heterocyclic group~~; lower alkylsulfonyl; lower alkoxy optionally substituted with lower alkoxy, N,N-di(lower)alkylcarbamoyl or halogen; cycloalkyloxy; lower alkylthio; or lower alkylsufinyl;

R³ is lower alkyl optionally substituted with amino, carbamoylamino or lower alkylsulfonylamino; halogen; cyano; hydroxy; lower alkanoyloxy; lower alkylendioxy; lower alkoxy optionally substituted with aryl, hydroxy,

cyano, amino, lower alkoxycarbonylamino, lower alkylsulfonylamino or carbamoylamino; nitro; amino; ~~heterocyclic group~~; lower alkylthio; lower alkylsulfinyl; or lower alkylsulfonyl;

R^4 is ~~hydrogen; cyano; amino optionally substituted with phthaloyl or lower alkyl; aryl; heterocyclic group; lower alkoxy; hydroxy; lower alkylsulfonyloxy; lower alkanoyloxy; lower alkyl substituted with tritylamino and lower alkoxycarbonyl; amino and lower alkoxycarbonyl; amino and carboxy; amino and carbamoyl; or amino and hydroxy; N-lower alkoxycarbonyl-N-lower alkylamino; lower alkanoyl optionally substituted with halogen; carboxy; lower alkylsulfonyl; sulfo; lower alkylsilyloxy; lower alkoxycarbonyl; sulfamoyl optionally substituted with lower alkyl; carbamoyl optionally substituted with lower alkyl; lower alkylthio; lower alkylsulfinyl; carbamoyloxy; thioureido; or~~
a group of the formula:



in which G is -CO- ~~or~~ -SO₂-;

J is -N(R⁶) -

(wherein R⁶ is hydrogen or lower alkyl) ; and

R⁵ is amino optionally substituted with lower alkoxycarbonyl or lower alkyl; lower alkyl optionally substituted with hydroxy, lower alkoxycarbonylamino, lower alkanoyloxy, amino or halogen; lower alkoxy; hydrogen; ~~heterocyclic group~~; or aryl;

X is O, S, SO or SO₂;

Y is CH ~~or~~ N;

Z is lower alkylene or lower alkenylene; and

m is 0 or 1;

~~provided that when R⁴ is hydrogen;~~

~~then R³ is lower alkyl substituted with amino, carbamoylamino or lower alkylsulfonylamino; or lower alkoxy substituted with aryl, hydroxy, cyano, amino, lower alkoxy carbonylamino, lower alkylsulfonylamino or carbamoylamino;~~

or a salt salts thereof.


Claim 2 (Currently Amended): The compound of Claim 1, wherein

R¹ is hydrogen;

R² is lower alkyl optionally substituted with halogen, hydroxy, lower alkoxyimino or lower alkoxy; cycloalkyl; halogen; lower alkoxy optionally substituted with halogen; or lower alkylthio;

R³ is lower alkoxy optionally substituted with aryl, hydroxy, cyano, amino, lower alkoxy carbonylamino, lower alkylsulfonylamino or carbamoylamino;

~~R⁴ is a group of the formula:~~



~~in which R⁵, G and J are each as defined in claim 1;~~

X is O or S; and


Z is lower alkylene.

Claim 3 (Currently Amended): The compound of Claim 2, wherein

R² is lower alkyl optionally substituted with halogen; cycloalkyl; halogen; or lower alkoxy optionally substituted with halogen;

R³ is lower alkoxy;

~~R⁴ is a group of the formula:~~



~~in which G is CO or SO₂;~~

J is -NH- and

R⁵ is amino or lower alkyl; and

X is O.

Claim 4 (Original): The compound of Claim 3, which is

N-(2-(4-[3-chloro-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]-phenoxy)ethyl)urea,

N-(4-[3-(difluoromethyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]benzyl)methanesulfonamide,

N-(4-[3-(difluoromethyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]benzyl)urea,

N-(2-(4-[3-(difluoromethyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy)ethyl)urea,

N-(2-(4-[1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy)ethyl)urea,

N-(2-(4-[3-(difluoromethyl)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy)ethyl)urea,

N-(2-(4-[3-cyclopropyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenoxy)ethyl)urea,

N-(2-(4-[3-(difluoromethyl)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy)ethyl)urea,

N-(2-(4-[1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenoxy)ethyl)acetamide, or

N-(2-(4-[3-(2,2-difluoroethoxy)-1-(6-methoxy-3-pyridinyl)-1H-pyrazol-5-yl]phenoxy)ethyl)urea.

Claim 5: (Canceled).

Claim 6 (Original): A pharmaceutical composition comprising the compound of Claim 1, as an active ingredient, in association with a pharmaceutically non-toxic carrier or excipient.

Claim 7: (Canceled).


Claim 8 (Currently Amended): A method for treatment ~~and/or prevention~~ of inflammatory conditions, ~~pain various pains~~, collagen diseases, autoimmune diseases, ~~various~~ immunity diseases, analgesic, thrombosis, cancer or neurodegenerative diseases which comprises administering an effective amount of the compound of Claim 1 to a human beings or an animals.

Claims 9-12: (Canceled).


Claim 13 (New): A method of treating an inflammatory condition, comprising administering an effective amount of the compound of Claim 1 to a human being or an animal.

Claim 14 (New): A process of preparing a compound of Claim 1 or a salt thereof, comprising:


1) reacting a compound of the formula:



or a salt thereof with a compound of the formula:




or a salt thereof in the acidic condition to provide a compound of the formula:




or a salt thereof, in the above formulas,

or


2) reacting a compound of the formula:



or a salt thereof with a compound (V) of the formula:



or a salt thereof to provide a compound of the formula:



or a salt thereof,

wherein R^1 , R^2 , R^3 , R^4 , X, Y, Z and m are each as defined in Claim 1,

Xa is O or S, and

Q is hydroxy or an acid residue.

SUPPORT FOR THE AMENDMENTS

The amendments to the pending claims and newly-added Claims 13-14 are supported by the specification. Accordingly, no new matter is believed to have been added to the present application by the amendments submitted above.